Study of Adalloce safety and effects in rheumatoid or ankylosing arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This is an observational study that follows people with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) who are planning to start Adalloce. It aims to understand how safe the medicine is and how well it works in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 20 and 74 years old when you sign consent
- Have been diagnosed with RA or AS at least 3 months before enrolling
- Your doctor is planning to prescribe Adalloce for you
- You have never taken Adalloce before
- You can sign a written consent form after understanding the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This trial is for people with ankylosing spondylitis (a type of arthritis that affects the spine) who are otherwise healthy. It may test a treatment to see if it helps control symptoms, whether your disease is active or stable.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests a new drug called CND319 in healthy volunteers and people with rheumatoid arthritis or Sjögren's disease. The goal is to see if it is safe and how the body responds to it.
This study looks at a specific enzyme (15-hydroxyprostaglandin dehydrogenase) in people with osteoarthritis or ankylosing spondylitis. It may help researchers understand these conditions better and find new treatment targets.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.